5 Takeaways From the Anthem-Aspire Acquisition
Precision for Value’s Joseph Honcz shares top takeaways from the recent Anthem-Aspire acquisition, and the continued effort by managed care entities to enter the business of senior care management.
PHE’s Snider Presents New CAR T-cell Study at ASCO: CAR T-cell Therapy Benefit Dependent on Prompt Treatment
At the ASCO Annual Meeting in Chicago, PHE Senior Director, Policy & Economics Julia Thornton-Snider, PhD presented a recently-completed study on the impact of treatment delays for patients with pediatric leukemia. (more…)
First Look at Trump Administration’s ‘American Patients First’ Blueprint
In this article Larry Blandford, EVP and managing partner at Precision Xtract, offers initial impressions of the Trump Administration’s blueprint to lower drug prices – American Patients First. (more…)
PM360 Names Dan Renick as Elite Award Winner
Precision is pleased to announce that Dan Renick has been named as one of PM360 Magazine’s annual ELITE Award winners. Congratulations, Dan! (more…)
The Evolving Reimbursement Landscape – Considerations for Clinical Trial Design
As a guest contributor to Clinical Leader, Precision for Value’s Dominic Galante examines the importance of payer perspective during clinical R&D. With a greater push for evidence-based value, scientists are starting to incorporate payer insights earlier in drug development.
The Appeal of Value Assessment at ISPOR 2018
At this year’s ISPOR, Precision Xtract’s Larry Blandford and Precision Health Economics’ Jason Shafrin met with BioPharm Insights to illuminate the importance of shifting to value-based assessment and examine reasons why US payers are slow to adopt the model. (more…)
New Reimbursement May Level Playing Field for Biosimilars
The Bipartisan Budget Act of 2018 (BBA 2018) directly affects Medicare Part D drugs, but its impact could expand beyond. Precision for Value’s Joanne Mai and Andrew Cournoyer cover how this change in the Medicare coverage gap program represents a small step toward encouraging biosimilar development, containing drug prices, and improving patient access. (more…)
FDA’s Draft Guidance and Its Impact on Development Programs
Precision for Value’s Andrew Cournoyer is featured in Specialty Pharmacy News discussing the FDA’s discretion over the Biologics Price Competition and Innovation Act of 2009 (BPCIA) and the impact the deemed drafted guidance has over biosimilar adoption. (more…)
Insights Into Value-Based Agreements
In the Journal of Clinical Pathways our experts identify key factors influencing the implementation of value-based contracting. (more…)
Developments in cellular and genetic therapies force reevaluation of reimbursement process
As new cellular and genetic therapies are attracting interest in regenerative medicine, payers are struggling to stave off large upfront costs. (more…)